A citation-based method for searching scientific literature

Arun Sanyal, Edgar D Charles, Brent A Neuschwander-Tetri, Rohit Loomba, Stephen A Harrison, Manal F Abdelmalek, Eric J Lawitz, Dina Halegoua-DeMarzio, Sudeep Kundu, Stephanie Noviello, Yi Luo, Rose Christian. Lancet 2019
Times Cited: 241







List of co-cited articles
1401 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome,[...]. Lancet 2019
488
37

Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study.
Edgar D Charles, Brent A Neuschwander-Tetri, Juan Pablo Frias, Sudeep Kundu, Yi Luo, Giridhar S Tirucherai, Rose Christian. Obesity (Silver Spring) 2019
117
36

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Brent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, Joel E Lavine, Mark L Van Natta, Manal F Abdelmalek, Naga Chalasani, Srinivasan Dasarathy, Anna Mae Diehl, Bilal Hameed,[...]. Lancet 2015
34

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Stephen A Harrison, Mustafa R Bashir, Cynthia D Guy, Rong Zhou, Cynthia A Moylan, Juan P Frias, Naim Alkhouri, Meena B Bansal, Seth Baum, Brent A Neuschwander-Tetri,[...]. Lancet 2019
224
34

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
Gregory Gaich, Jenny Y Chien, Haoda Fu, Leonard C Glass, Mark A Deeg, William L Holland, Alexei Kharitonenkov, Thomas Bumol, Holger K Schilske, David E Moller. Cell Metab 2013
597
34

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
944
32

FGF-21 as a novel metabolic regulator.
Alexei Kharitonenkov, Tatiyana L Shiyanova, Anja Koester, Amy M Ford, Radmila Micanovic, Elizabeth J Galbreath, George E Sandusky, Lisa J Hammond, Julie S Moyers, Rebecca A Owens,[...]. J Clin Invest 2005
32

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.
Saswata Talukdar, Yingjiang Zhou, Dongmei Li, Michelle Rossulek, Jennifer Dong, Veena Somayaji, Yan Weng, Ronald Clark, Adhiraj Lanba, Bryn M Owen,[...]. Cell Metab 2016
290
32

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Stephen A Harrison, Mary E Rinella, Manal F Abdelmalek, James F Trotter, Angelo H Paredes, Hays L Arnold, Marcelo Kugelmas, Mustafa R Bashir, Mark J Jaros, Lei Ling,[...]. Lancet 2018
263
30

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Vlad Ratziu, Stephen A Harrison, Sven Francque, Pierre Bedossa, Philippe Lehert, Lawrence Serfaty, Manuel Romero-Gomez, Jérôme Boursier, Manal Abdelmalek, Steve Caldwell,[...]. Gastroenterology 2016
636
30

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Philip N Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison. N Engl J Med 2021
357
28

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
Jing Xu, David J Lloyd, Clarence Hale, Shanaka Stanislaus, Michelle Chen, Glenn Sivits, Steven Vonderfecht, Randy Hecht, Yue-Sheng Li, Richard A Lindberg,[...]. Diabetes 2009
819
26

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Keyur Patel, Stephen A Harrison, Magdy Elkhashab, James F Trotter, Robert Herring, Sergio E Rojter, Zeid Kayali, Vincent Wai-Sun Wong, Susan Greenbloom, Saumya Jayakumar,[...]. Hepatology 2020
124
26

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial.
Stephen A Harrison, Peter J Ruane, Bradley L Freilich, Guy Neff, Rashmee Patil, Cynthia A Behling, Chen Hu, Erica Fong, Brittany de Temple, Erik J Tillman,[...]. Nat Med 2021
51
50

Fibroblast growth factor 21 corrects obesity in mice.
Tamer Coskun, Holly A Bina, Michael A Schneider, James D Dunbar, Charlie C Hu, Yanyun Chen, David E Moller, Alexei Kharitonenkov. Endocrinology 2008
755
25

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
24

Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21.
Takeshi Inagaki, Paul Dutchak, Guixiang Zhao, Xunshan Ding, Laurent Gautron, Vinay Parameswara, Yong Li, Regina Goetz, Moosa Mohammadi, Victoria Esser,[...]. Cell Metab 2007
24

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Stephen A Harrison, Guy Neff, Cynthia D Guy, Mustafa R Bashir, Angelo H Paredes, Juan P Frias, Ziad Younes, James F Trotter, Nadege T Gunn, Sam E Moussa,[...]. Gastroenterology 2021
93
25

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
23

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
23

Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states.
Michael K Badman, Pavlos Pissios, Adam R Kennedy, George Koukos, Jeffrey S Flier, Eleftheria Maratos-Flier. Cell Metab 2007
23

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Stephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, Natalie Bzowej, Raj Vuppalanchi, Ziad Younes, Anita Kohli, Shiv Sarin, Stephen H Caldwell, Naim Alkhouri,[...]. J Hepatol 2020
171
22

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.
Alexei Kharitonenkov, Victor J Wroblewski, Anja Koester, Yun-Fei Chen, Cathleen K Clutinger, Xenia T Tigno, Barbara C Hansen, Armen B Shanafelt, Garret J Etgen. Endocrinology 2007
566
22

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
Rohit Loomba, Zeid Kayali, Mazen Noureddin, Peter Ruane, Eric J Lawitz, Michael Bennett, Lulu Wang, Eliza Harting, Jacqueline M Tarrant, Bryan J McColgan,[...]. Gastroenterology 2018
171
21

Mechanisms of NAFLD development and therapeutic strategies.
Scott L Friedman, Brent A Neuschwander-Tetri, Mary Rinella, Arun J Sanyal. Nat Med 2018
21

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Stephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, Mitchell L Shiffman, Anna Mae Diehl, Reem Ghalib, Eric J Lawitz, Don C Rockey, Raul Aguilar Schall, Catherine Jia,[...]. Gastroenterology 2018
171
19

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Stephen A Harrison, Naim Alkhouri, Beth A Davison, Arun Sanyal, Christopher Edwards, Jerry R Colca, Bo Hyun Lee, Rohit Loomba, Kenneth Cusi, Orville Kolterman,[...]. J Hepatol 2020
100
19

The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.
Rifaat Safadi, Fred M Konikoff, Mahmud Mahamid, Shira Zelber-Sagi, Maya Halpern, Tuvia Gilat, Ran Oren. Clin Gastroenterol Hepatol 2014
174
19

AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients.
Allegra Kaufman, Lubna Abuqayyas, William S Denney, Erik J Tillman, Tim Rolph. Cell Rep Med 2020
36
52

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
Vlad Ratziu, Arun Sanyal, Stephen A Harrison, Vincent Wai-Sun Wong, Sven Francque, Zachary Goodman, Guruprasad P Aithal, Kris V Kowdley, Star Seyedkazemi, Laurent Fischer,[...]. Hepatology 2020
130
18

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Kenneth Cusi, Beverly Orsak, Fernando Bril, Romina Lomonaco, Joan Hecht, Carolina Ortiz-Lopez, Fermin Tio, Jean Hardies, Celia Darland, Nicolas Musi,[...]. Ann Intern Med 2016
507
18

Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets.
Ffolliott M Fisher, Patricia C Chui, Imad A Nasser, Yury Popov, Jeremy C Cunniff, Thomas Lundasen, Alexei Kharitonenkov, Detlef Schuppan, Jeffrey S Flier, Eleftheria Maratos-Flier. Gastroenterology 2014
175
17

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.
Stephen A Harrison, Stephen J Rossi, Angelo H Paredes, James F Trotter, Mustafa R Bashir, Cynthia D Guy, Rajarshi Banerjee, Mark J Jaros, Sandra Owers, Bryan A Baxter,[...]. Hepatology 2020
127
17


Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding.
Kathleen R Markan, Meghan C Naber, Magdalene K Ameka, Maxwell D Anderegg, David J Mangelsdorf, Steven A Kliewer, Moosa Mohammadi, Matthew J Potthoff. Diabetes 2014
368
17

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Rohit Loomba, Mazen Noureddin, Kris V Kowdley, Anita Kohli, Aasim Sheikh, Guy Neff, Bal Raj Bhandari, Nadege Gunn, Stephen H Caldwell, Zachary Goodman,[...]. Hepatology 2021
77
22

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Scott L Friedman, Vlad Ratziu, Stephen A Harrison, Manal F Abdelmalek, Guruprasad P Aithal, Juan Caballeria, Sven Francque, Geoffrey Farrell, Kris V Kowdley, Antonio Craxi,[...]. Hepatology 2018
393
16

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.
Naga Chalasani, Manal F Abdelmalek, Guadalupe Garcia-Tsao, Raj Vuppalanchi, Naim Alkhouri, Mary Rinella, Mazen Noureddin, Maxmillan Pyko, Mitchell Shiffman, Arun Sanyal,[...]. Gastroenterology 2020
117
15

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Stephen A Harrison, Zachary Goodman, Abdul Jabbar, Ravi Vemulapalli, Ziad H Younes, Bradley Freilich, Muhammad Y Sheikh, Jörn M Schattenberg, Zeid Kayali, Adam Zivony,[...]. J Hepatol 2020
107
15

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot, Ana Torres-Gonzalez, Bienvenido Gra-Oramas, Licet Gonzalez-Fabian, Scott L Friedman, Moises Diago, Manuel Romero-Gomez. Gastroenterology 2015
15

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
Mark L Hartman, Arun J Sanyal, Rohit Loomba, Jonathan M Wilson, Amir Nikooienejad, Ross Bray, Chrisanthi A Karanikas, Kevin L Duffin, Deborah A Robins, Axel Haupt. Diabetes Care 2020
91
16

Obesity is a fibroblast growth factor 21 (FGF21)-resistant state.
Ffolliott M Fisher, Patricia C Chui, Patrick J Antonellis, Holly A Bina, Alexei Kharitonenkov, Jeffrey S Flier, Eleftheria Maratos-Flier. Diabetes 2010
534
15

Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans.
Amos Baruch, Chin Wong, Leslie W Chinn, Anjali Vaze, Junichiro Sonoda, Thomas Gelzleichter, Shan Chen, Nicholas Lewin-Koh, Linda Morrow, Suresh Dheerendra,[...]. Proc Natl Acad Sci U S A 2020
36
41

The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic.
Leiluo Geng, Karen S L Lam, Aimin Xu. Nat Rev Endocrinol 2020
119
15

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
Rohit Loomba, Eric Lawitz, Parvez S Mantry, Saumya Jayakumar, Stephen H Caldwell, Hays Arnold, Anna Mae Diehl, C Stephen Djedjos, Ling Han, Robert P Myers,[...]. Hepatology 2018
344
14

FGF21 Mediates Endocrine Control of Simple Sugar Intake and Sweet Taste Preference by the Liver.
Stephanie von Holstein-Rathlou, Lucas D BonDurant, Lila Peltekian, Meghan C Naber, Terry C Yin, Kristin E Claflin, Adriana Ibarra Urizar, Andreas N Madsen, Cecilia Ratner, Birgitte Holst,[...]. Cell Metab 2016
213
14

FGF21 regulates metabolism and circadian behavior by acting on the nervous system.
Angie L Bookout, Marleen H M de Groot, Bryn M Owen, Syann Lee, Laurent Gautron, Heather L Lawrence, Xunshan Ding, Joel K Elmquist, Joseph S Takahashi, David J Mangelsdorf,[...]. Nat Med 2013
355
14

Understanding the Physiology of FGF21.
Ffolliott Martin Fisher, Eleftheria Maratos-Flier. Annu Rev Physiol 2016
422
14

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.
Jing Xu, Shanaka Stanislaus, Narumol Chinookoswong, Yvonne Y Lau, Todd Hager, Jennifer Patel, Hongfei Ge, Jen Weiszmann, Shu-Chen Lu, Melissa Graham,[...]. Am J Physiol Endocrinol Metab 2009
249
14

Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.
Albert M Kim, Veena R Somayaji, Jennifer Q Dong, Timothy P Rolph, Yan Weng, Jeffrey R Chabot, Kathryn E Gropp, Saswata Talukdar, Roberto A Calle. Diabetes Obes Metab 2017
77
18


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.